A clinical study to investigate the effect and safety of up to 6 months of treatment with inhaled Promixin in the treatment of chest infections causeed by Pseudomonas in people with a lung disease called bronchiectasis
- Registry ID
- EUCTR2008-005045-34
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- Profile Pharma Ltd
- Start date
- 2008-11-07
- Completion date
- 2012-02-03
- Last update
- 2026-08-16
Conditions
- non-CF bronchiectasis (CF = cystic fibrosis)
Summary
To demonstrate that inhaled Promixin, administered twice a day for up to 6 months, at a concentration of 1 MIU/mL via an I-neb with a 0.3 mL metering chamber, increases the time to a pulmonary exacerbation, compared to vehicle, in patients with non-cystic fibrosis bronchiectasis infected with P. aeruginosa susceptible to Promixin.
Locations
View on source registry